UBS Group Reaffirms Neutral Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “neutral” rating reissued by investment analysts at UBS Group in a research note issued to investors on Monday, MarketBeat Ratings reports. They currently have a $188.00 price target on the specialty pharmaceutical company’s stock, up from their prior price target of $163.00. UBS Group’s price objective would indicate a potential upside of 4.42% from the company’s current price.

Several other equities research analysts have also recently weighed in on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, October 8th. Needham & Company LLC reissued a “buy” rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Wall Street Zen upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Truist Financial upped their price objective on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a report on Thursday, August 28th. Finally, The Goldman Sachs Group lifted their target price on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research note on Friday, August 29th. Thirteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $195.67.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $180.05 on Monday. Jazz Pharmaceuticals has a 52 week low of $95.49 and a 52 week high of $182.99. The stock has a market capitalization of $10.94 billion, a PE ratio of -26.75, a PEG ratio of 8.49 and a beta of 0.29. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The stock’s fifty day moving average is $141.04 and its 200-day moving average is $123.74.

Insiders Place Their Bets

In related news, Director Bruce C. Cozadd sold 18,000 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $181.09, for a total transaction of $3,259,620.00. Following the completion of the sale, the director directly owned 390,826 shares of the company’s stock, valued at $70,774,680.34. The trade was a 4.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Robert Iannone sold 7,159 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $168.26, for a total value of $1,204,573.34. Following the completion of the transaction, the executive vice president directly owned 72,628 shares in the company, valued at $12,220,387.28. The trade was a 8.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 50,893 shares of company stock worth $8,559,699 over the last three months. Insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. CWM LLC grew its holdings in shares of Jazz Pharmaceuticals by 56.2% in the 1st quarter. CWM LLC now owns 1,259 shares of the specialty pharmaceutical company’s stock valued at $156,000 after buying an additional 453 shares during the period. Cetera Investment Advisers grew its stake in Jazz Pharmaceuticals by 4.4% in the first quarter. Cetera Investment Advisers now owns 10,536 shares of the specialty pharmaceutical company’s stock valued at $1,308,000 after acquiring an additional 444 shares during the period. Assetmark Inc. increased its holdings in shares of Jazz Pharmaceuticals by 16.0% in the first quarter. Assetmark Inc. now owns 843 shares of the specialty pharmaceutical company’s stock worth $105,000 after acquiring an additional 116 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Jazz Pharmaceuticals by 649.5% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 199,204 shares of the specialty pharmaceutical company’s stock worth $24,731,000 after purchasing an additional 172,626 shares during the period. Finally, LPL Financial LLC lifted its holdings in shares of Jazz Pharmaceuticals by 14.5% during the 1st quarter. LPL Financial LLC now owns 25,769 shares of the specialty pharmaceutical company’s stock valued at $3,199,000 after purchasing an additional 3,264 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.